Business Update
Global Access Program for HIV therapies to include additional countries
Published in Hepatitis Weekly, April 11th, 2005
The Gilead Access Program makes Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) available to physicians and treatment programs in countries at the no-profit prices of US$29.75 per month (US$0.99 per day) and US$24.71 per month (US$0.82 per day), respectively.
Gilead's global Access Program was initiated in April 2003 and originally served 68 countries, including every country in Africa and 15 additional...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-04-11)
More Articles from Hepatitis Weekly
- Cancer Therapy
Cancer patients with viral hepatitis benefit from hepatic artery chemotherapy - Hepatitis B Prevention
Hepatitis B vaccine does not stop viral recurrence after liver transplantation - Hepatitis B Therapy
Interferon triggers anti-inflammatory activity in chronic hepatitis B patients - Oncology
Genes predispose breast cancer patients to tamoxifen-induced fatty liver - Virology
Several factors drive the effect of donor age on liver transplant outcomes - Adverse Drug Reaction
Alemtuzumab immunotherapy reactivates hepatitis B virus infection - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
